Emergency physician-directed treatment of patients with acute stroke using tissue plasminogen activator (t-PA) is as safe as treatment directed by an acute stroke team, according to the results of a retrospective study presented at the American Heart Association's (AHA's) International Stroke Conference 2007 in San Francisco, Calif.
IV t-PA use was assessed over a 10-year period (from January 1, 1996, to January 1, 2005) in stroke patients treated in the emergency departments of 4 southeastern Michigan hospitals without a dedicated acute thrombolytic stroke team.
During this period, 95 individual emergency physicians used t-PA to treat 273 patients with acute strokes. The mean age of the patients was 68 years and 55% were men. The average time from symptom onset to treatment was 154 minutes. The treated patients' characteristics were similar to those of patients treated in the seminal 1996 National Institute of Neurological Disorders and Stroke (NINDS) study in which the safety and efficacy of IV t-PA for the treatment of acute ischemic stroke was established.
Mortality at 1 year, the primary end point of the study, was 27.8%, which was consistent with both the treatment and placebo groups in the NINDS study (P=.046). The relative risk of mortality was 1.16 (95% CI, 0.88–1.52) compared with the NINDS group of patients who received treatment, and 1.00 (95% CI, 0.77–1.30) compared with the NINDS placebo recipients, both nonsignificant differences.
"Secondary safety measures were also consistent with the experience of the NINDS trial," said Phillip A Scott, MD, assistant professor, department of emergency medicine, University of Michigan, Ann Arbor. The rate of any intracerebral hemorrhage (ICH) within 36 hours of treatment was 9.9% (RR=0.94; 95% CI, 058–1.51) compared with patients treated with t-PA in the NINDS study. The rate of symptomatic/significant ICH by CT criteria was 6.6% (RR=1.03; 95% CI, 0.56–1.90) compared with the NINDS t-PA group.
Protocol violations occurred in the emergency department in 26% of patients. Of these violations, 61% were for treatment beyond 3 hours. Among the patients treated beyond 3 hours, the median time to treatment from symptom onset was 195 minutes. The rate of protocol violations "represents an opportunity for improvement through systems of quality management and continuing education," Dr Scott said. "While a third of the out-of-window treatments were less than 5 minutes beyond the window... many were substantially greater. Given the other safety measures, the clinical implications of these violations seem limited, but suggest a potential need for continued monitoring."
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More